Offer - Urjas Oil for just ₹ 1 X
Caberlact 0.25 Tablet is a commercial drug that is prescribed in the form of Tablet. It is primarily used for the treatment of Acromegaly, Prolactinoma.
Medical history of the patient along with age and gender determines the dosage of Caberlact 0.25 Tablet. The condition it has been prescribed for, and the route of administration also determine the right dosage. Detailed information has been provided in the dosage section.
Besides the aforementioned side effects, there are other adverse effects of Caberlact 0.25 Tablet as well, which are listed below. Usually, these side effects of Caberlact 0.25 Tablet go away soon, and do not persist beyond the duration of the treatment. Consult your doctor if these side effects become worse or stay for a longer duration.
Caberlact 0.25 Tablet's effect during pregnancy is Mild and Severe while nursing. It is important to know if Caberlact 0.25 Tablet has any effect on the kidney, liver and heart. Information on such adverse effects, if any, has been given in the Caberlact 0.25 Tablet related warnings section.
Caberlact 0.25 Tablet can cause adverse effects in certain medical conditions. It is strongly recommended to avoid Caberlact 0.25 Tablet in conditions like High Blood Pressure, Heart Disease, Depression. Some other conditions that can be affected by Caberlact 0.25 Tablet are listed in the contraindications section below.
Drug reaction of Caberlact 0.25 Tablet with other medicines has been reported. See below for a complete list.
Along with the above-mentioned precautions, remember that taking Caberlact 0.25 Tablet is considered not safe while driving, and is not addictive.
Caberlact 0.25 Tablet is used to treat the following -
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
Age Group | Dosage |
Adult |
|
Geriatric |
|
Is the use of Caberlact 0.25 Tablet safe for pregnant women?
Caberlact rarely shows harmful effects in in pregnant ladies. Even if it does, the effects are mild
Is the use of Caberlact 0.25 Tablet safe during breastfeeding?
Caberlact may cause serious side effects in breastfeeding women, so do not take this drug without doctor's advice.
What is the effect of Caberlact 0.25 Tablet on the Kidneys?
Kidney can be affected by Caberlact. If you experience any unwanted effects of this drug, stop taking it. You should take it again only after medical advice.
What is the effect of Caberlact 0.25 Tablet on the Liver?
You may experience side effects on your liver after taking Caberlact. If this happens, then discontinue its use. Consult your medical practitioner, do as he/she suggests.
What is the effect of Caberlact 0.25 Tablet on the Heart?
You may experience side effects on your heart after taking Caberlact. If this happens, then discontinue its use. Consult your medical practitioner, and do as he/she suggests.
If you are suffering from any of the following diseases, you should not take Caberlact 0.25 Tablet unless your doctor advises you to do so -
Is this Caberlact 0.25 Tablet habit forming or addictive?
No, there is no any evidence that Caberlact 0.25 Tablet is addictive.
Is it safe to drive or operate heavy machinery when consuming?
You may feel sleepy or tired after taking Caberlact 0.25 Tablet. So it is best to avoid driving.
Is it safe?
Yes, Caberlact 0.25 Tablet is safe but you must consult your doctor before taking it.
Is it able to treat mental disorders?
Caberlact 0.25 Tablet is unable to treat or cure mental disorders.
Interaction between Food and Caberlact 0.25 Tablet
Due to the absence of research, it is difficult to say how Caberlact 0.25 Tablet and food will interact.
Interaction between Alcohol and Caberlact 0.25 Tablet
Taking Caberlact 0.25 Tablet and alcohol together may cause some problems. If you notice any of these side effects, it is best to go to your doctor.
This medicine data has been created by -
B.Pharma, Pharmacy
5 Years of Experience
References
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 174-176
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 239-240
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Dostinex® (cabergoline)